BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 34257577)

  • 1. Factors Associated with Survival From Xp11.2 Translocation Renal Cell Carcinoma Diagnosis-A Systematic Review and Pooled Analysis.
    Wu Y; Chen S; Zhang M; Liu K; Jing J; Pan K; Zhang L; Xu B; Lu X; Chen M
    Pathol Oncol Res; 2021; 27():610360. PubMed ID: 34257577
    [No Abstract]   [Full Text] [Related]  

  • 2. Preoperative neutrophil-to-lymphocyte ratio predicts the surgical outcome of Xp11.2 translocation/TFE3 renal cell carcinoma patients.
    Agizamhan S; Qu F; Liu N; Sun J; Xu W; Zhang L; Guo H; Gan W
    BMC Urol; 2018 Jun; 18(1):60. PubMed ID: 29890986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-204-5p: A novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma.
    Kurahashi R; Kadomatsu T; Baba M; Hara C; Itoh H; Miyata K; Endo M; Morinaga J; Terada K; Araki K; Eto M; Schmidt LS; Kamba T; Linehan WM; Oike Y
    Cancer Sci; 2019 Jun; 110(6):1897-1908. PubMed ID: 31006167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postoperative recurrence of adult renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion.
    Wang Z; Liu N; Gan W; Li X; Zhang G; Li D; Guo H
    J Int Med Res; 2017 Aug; 45(4):1287-1296. PubMed ID: 28587544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.
    Malouf GG; Camparo P; Oudard S; Schleiermacher G; Theodore C; Rustine A; Dutcher J; Billemont B; Rixe O; Bompas E; Guillot A; Boccon-Gibod L; Couturier J; MoliniƩ V; Escudier B
    Ann Oncol; 2010 Sep; 21(9):1834-1838. PubMed ID: 20154303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusions: Clinical Features, Treatments and Prognosis.
    Liu N; Wang Z; Gan W; Xiong L; Miao B; Chen X; Guo H; Li D
    PLoS One; 2016; 11(11):e0166897. PubMed ID: 27893792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Xp11.2 Translocation renal cell carcinomas have a poorer prognosis than non-Xp11.2 translocation carcinomas in children and young adults: a meta-analysis.
    Qiu Rao ; Bing Guan ; Zhou XJ
    Int J Surg Pathol; 2010 Dec; 18(6):458-64. PubMed ID: 20643670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage.
    Ellis CL; Eble JN; Subhawong AP; Martignoni G; Zhong M; Ladanyi M; Epstein JI; Netto GJ; Argani P
    Mod Pathol; 2014 Jun; 27(6):875-86. PubMed ID: 24309327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathologic, treatment and prognosis study of 46 Xp11.2 translocation/TFE3 gene fusion renal cell carcinomas.
    Zhou J; Zhao L; Yang Z; Chen Y; Wu X; Xue W
    BMC Urol; 2022 Jul; 22(1):109. PubMed ID: 35850864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical features of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusions-single-center study].
    Ma WL; Liu N; Zhuang WY; Li XG; Zhang GT; Gan WD; Guo HQ
    Zhonghua Yi Xue Za Zhi; 2018 Oct; 98(38):3068-3073. PubMed ID: 30392265
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical characteristics of XP11.2 translocation/TFE3 gene fusion renal cell carcinoma: a systematic review and meta-analysis of observational studies.
    Cheng X; Gan W; Zhang G; Li X; Guo H
    BMC Urol; 2016 Jul; 16(1):40. PubMed ID: 27401463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Xp11.2 translocation renal neoplasm with features of TFE3 rearrangement associated renal cell carcinoma and Xp11 translocation renal mesenchymal tumor with melanocytic differentiation harboring NONO-TFE3 fusion gene.
    Yu W; Wang Y; Rao Q; Jiang Y; Zhang W; Li Y
    Pathol Res Pract; 2019 Sep; 215(9):152521. PubMed ID: 31277953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum.
    Argani P; Olgac S; Tickoo SK; Goldfischer M; Moch H; Chan DY; Eble JN; Bonsib SM; Jimeno M; Lloreta J; Billis A; Hicks J; De Marzo AM; Reuter VE; Ladanyi M
    Am J Surg Pathol; 2007 Aug; 31(8):1149-60. PubMed ID: 17667536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.
    Rao Q; Williamson SR; Zhang S; Eble JN; Grignon DJ; Wang M; Zhou XJ; Huang W; Tan PH; Maclennan GT; Cheng L
    Am J Surg Pathol; 2013 Jun; 37(6):804-15. PubMed ID: 23598965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological characteristics of pediatric renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.
    Song HC; Sun N; Zhang WP; He L; Fu L; Huang C
    J Pediatr Surg; 2014 Apr; 49(4):539-42. PubMed ID: 24726108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The incidence of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion in Saudi adult patients with renal cancer: a retrospective tissue microarray analysis.
    Al-Maghrabi J; Mufti S; Gomaa W
    Pol J Pathol; 2018; 69(4):376-383. PubMed ID: 30786687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusions: clinical experience and literature review.
    He J; Chen X; Gan W; Zhu B; Fan X; Guo H; Jia R
    Future Oncol; 2015; 11(24):3243-52. PubMed ID: 26169997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen associates with female predominance in Xp11.2 translocation renal cell carcinoma.
    Lu Y; Zhu Y; Ma W; Liu N; Dong X; Shi Q; Yu F; Guo H; Li D; Gan W
    Sci Rep; 2023 Apr; 13(1):6141. PubMed ID: 37061606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unravelling the mysteries of Xp11.2 translocation-associated renal cell carcinoma: A case report with a review of the literature.
    Suneel R; Gupta P; Sekar A; Gupta N; Saxena A
    Cytopathology; 2023 Jul; 34(4):367-376. PubMed ID: 37118914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Newly designed break-apart and ASPL-TFE3 dual-fusion FISH assay are useful in diagnosing Xp11.2 translocation renal cell carcinoma and ASPL-TFE3 renal cell carcinoma: a STARD-compliant article.
    Chen X; Yang Y; Gan W; Xu L; Ye Q; Guo H
    Medicine (Baltimore); 2015 May; 94(19):e873. PubMed ID: 25984679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.